vs
ETSY INC（ETSY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ETSY INC的季度营收约是Revvity的1.1倍（$831.5M vs $772.1M），Revvity净利率更高（12.7% vs 12.6%，领先0.2%），ETSY INC同比增速更快（7.6% vs 5.9%），ETSY INC自由现金流更多（$671.2M vs $161.8M），过去两年ETSY INC的营收复合增速更高（13.3% vs 9.0%）
Etsy是美国电商企业，主打手工制品、复古商品及手工耗材交易，平台品类覆盖珠宝首饰、服饰、家居装饰、家具、玩具、艺术品等。平台规定复古商品需至少有20年历史，卖家可开设独立店铺，每件上架商品收取0.2美元挂牌费，2013年起平台也允许量产商品入驻销售。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ETSY vs RVTY — 直观对比
营收规模更大
ETSY
是对方的1.1倍
$772.1M
营收增速更快
ETSY
高出1.8%
5.9%
净利率更高
RVTY
高出0.2%
12.6%
自由现金流更多
ETSY
多$509.4M
$161.8M
两年增速更快
ETSY
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $831.5M | $772.1M |
| 净利润 | $104.7M | $98.4M |
| 毛利率 | 54.8% | — |
| 营业利润率 | 59.6% | 14.5% |
| 净利率 | 12.6% | 12.7% |
| 营收同比 | 7.6% | 5.9% |
| 净利润同比 | 398.3% | 3.9% |
| 每股收益（稀释后） | $0.89 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ETSYRVTY
| Q1 26 | $831.5M | — | ||
| Q4 25 | $881.6M | $772.1M | ||
| Q3 25 | $678.0M | $698.9M | ||
| Q2 25 | $672.7M | $720.3M | ||
| Q1 25 | $651.2M | $664.8M | ||
| Q4 24 | $852.2M | $729.4M | ||
| Q3 24 | $662.4M | $684.0M | ||
| Q2 24 | $647.8M | $691.7M |
净利润ETSYRVTY
| Q1 26 | $104.7M | — | ||
| Q4 25 | $110.7M | $98.4M | ||
| Q3 25 | $75.5M | $46.7M | ||
| Q2 25 | $28.8M | $53.9M | ||
| Q1 25 | $-52.1M | $42.2M | ||
| Q4 24 | $129.9M | $94.6M | ||
| Q3 24 | $57.4M | $94.4M | ||
| Q2 24 | $53.0M | $55.4M |
毛利率ETSYRVTY
| Q1 26 | 54.8% | — | ||
| Q4 25 | 73.1% | — | ||
| Q3 25 | 71.3% | 53.6% | ||
| Q2 25 | 71.2% | 54.5% | ||
| Q1 25 | 70.5% | 56.5% | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 72.0% | 56.3% | ||
| Q2 24 | 71.6% | 55.7% |
营业利润率ETSYRVTY
| Q1 26 | 59.6% | — | ||
| Q4 25 | 14.7% | 14.5% | ||
| Q3 25 | 12.2% | 11.7% | ||
| Q2 25 | 11.4% | 12.6% | ||
| Q1 25 | -3.4% | 10.9% | ||
| Q4 24 | 18.2% | 16.3% | ||
| Q3 24 | 13.1% | 14.3% | ||
| Q2 24 | 10.8% | 12.4% |
净利率ETSYRVTY
| Q1 26 | 12.6% | — | ||
| Q4 25 | 12.6% | 12.7% | ||
| Q3 25 | 11.1% | 6.7% | ||
| Q2 25 | 4.3% | 7.5% | ||
| Q1 25 | -8.0% | 6.4% | ||
| Q4 24 | 15.2% | 13.0% | ||
| Q3 24 | 8.7% | 13.8% | ||
| Q2 24 | 8.2% | 8.0% |
每股收益（稀释后）ETSYRVTY
| Q1 26 | $0.89 | — | ||
| Q4 25 | $1.00 | $0.86 | ||
| Q3 25 | $0.63 | $0.40 | ||
| Q2 25 | $0.25 | $0.46 | ||
| Q1 25 | $-0.49 | $0.35 | ||
| Q4 24 | $1.01 | $0.77 | ||
| Q3 24 | $0.45 | $0.77 | ||
| Q2 24 | $0.41 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $2.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ETSYRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.4B | $919.9M | ||
| Q3 25 | $1.2B | $931.4M | ||
| Q2 25 | $1.2B | $991.8M | ||
| Q1 25 | $649.2M | $1.1B | ||
| Q4 24 | $811.2M | $1.2B | ||
| Q3 24 | $818.9M | $1.2B | ||
| Q2 24 | $759.2M | $2.0B |
总债务ETSYRVTY
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益ETSYRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-1.1B | $7.3B | ||
| Q3 25 | $-1.1B | $7.4B | ||
| Q2 25 | $-1.1B | $7.6B | ||
| Q1 25 | $-910.3M | $7.6B | ||
| Q4 24 | $-758.9M | $7.7B | ||
| Q3 24 | $-624.3M | $7.9B | ||
| Q2 24 | $-635.0M | $7.9B |
总资产ETSYRVTY
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.8B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $725.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $671.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 80.7% | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 6.93× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.3B | $509.4M |
8季度趋势，按日历期对齐
经营现金流ETSYRVTY
| Q1 26 | $725.0M | — | ||
| Q4 25 | $317.1M | $182.0M | ||
| Q3 25 | $219.0M | $138.5M | ||
| Q2 25 | $108.1M | $134.3M | ||
| Q1 25 | $49.2M | $128.2M | ||
| Q4 24 | $315.0M | $174.2M | ||
| Q3 24 | $217.4M | $147.9M | ||
| Q2 24 | $151.1M | $158.6M |
自由现金流ETSYRVTY
| Q1 26 | $671.2M | — | ||
| Q4 25 | $315.9M | $161.8M | ||
| Q3 25 | $215.0M | $120.0M | ||
| Q2 25 | $101.3M | $115.5M | ||
| Q1 25 | $45.9M | $112.2M | ||
| Q4 24 | $310.9M | $149.8M | ||
| Q3 24 | $213.2M | $125.6M | ||
| Q2 24 | $147.4M | $136.6M |
自由现金流率ETSYRVTY
| Q1 26 | 80.7% | — | ||
| Q4 25 | 35.8% | 21.0% | ||
| Q3 25 | 31.7% | 17.2% | ||
| Q2 25 | 15.1% | 16.0% | ||
| Q1 25 | 7.1% | 16.9% | ||
| Q4 24 | 36.5% | 20.5% | ||
| Q3 24 | 32.2% | 18.4% | ||
| Q2 24 | 22.8% | 19.7% |
资本支出强度ETSYRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% |
现金转化率ETSYRVTY
| Q1 26 | 6.93× | — | ||
| Q4 25 | 2.86× | 1.85× | ||
| Q3 25 | 2.90× | 2.97× | ||
| Q2 25 | 3.75× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.42× | 1.84× | ||
| Q3 24 | 3.79× | 1.57× | ||
| Q2 24 | 2.85× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ETSY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
